Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 2 | -$0.27 | -$0.05 | -$0.18 |
Q2 2024 | 2 | -$0.25 | -$0.05 | -$0.17 |
Q3 2024 | 3 | -$0.26 | -$0.05 | -$0.17 |
Q4 2024 | 5 | -$0.20 | -$0.10 | -$0.15 |
Q1 2025 | 2 | -$0.23 | -$0.14 | -$0.19 |
Q2 2025 | 1 | -$0.28 | -$0.06 | -$0.19 |
Q3 2025 | 1 | -$0.28 | -$0.06 | -$0.18 |
Q4 2025 | 1 | -$0.27 | -$0.05 | -$0.18 |
Q1 2026 | 1 | -$0.28 | -$0.06 | -$0.18 |
Q2 2026 | 1 | -$0.26 | -$0.05 | -$0.17 |
Q3 2026 | 1 | -$0.26 | -$0.05 | -$0.17 |
Q4 2026 | 1 | -$0.26 | -$0.05 | -$0.17 |
Mersana Therapeutics, Inc. last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-0.09 earnings per share for the quarter, topping analysts' consensus estimates of $-0.18 by $0.09. The company had revenue of 12.60 M for the quarter and had revenue of 36.86 M for the year. Mersana Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.48 diluted earnings per share) and currently has a price-to-earnings ratio of -2.66. Mersana Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/13/2024 | Q3 2024 | -$0.18 | -$0.09 | 0.09 | $7.53 M | $12.60 M |
08/13/2024 | Q2 2024 | -$0.18 | -$0.20 | -0.02 | $8.72 M | $2.29 M |
05/09/2024 | Q1 2024 | -$0.18 | -$0.16 | 0.02 | $9.25 M | |
02/28/2024 | Q4 2023 | -$0.20 | -$0.16 | 0.04 | $10.70 M | |
11/07/2023 | Q3 2023 | -$0.31 | -$0.35 | -0.04 | $9.60 M | $7.70 M |
08/08/2023 | Q2 2023 | -$0.39 | -$0.47 | -0.08 | $12.93 M | $10.65 M |
05/09/2023 | Q1 2023 | -$0.41 | -$0.53 | -0.12 | $7.80 M | |
02/28/2023 | Q4 2022 | -$0.47 | -$0.45 | 0.02 | $14.69 M | |
11/07/2022 | Q3 2022 | -$0.09 | -$0.61 | -0.52 | $56.78 M | $5.57 M |
08/08/2022 | Q2 2022 | -$0.50 | -$0.55 | -0.05 | $2.20 M | $4.28 M |
05/09/2022 | Q1 2022 | -$0.31 | -$0.60 | -0.29 | $2.04 M | |
02/28/2022 | Q4 2021 | -$0.67 | -$0.68 | -0.01 | $11,000 | |
11/09/2021 | Q3 2021 | -$0.58 | -$0.63 | -0.05 | $120,500 | $11,000 |
08/06/2021 | Q2 2021 | -$0.50 | -$0.59 | -0.09 | $170,000 | $11,000 |
05/10/2021 | Q1 2021 | -$0.39 | -$0.50 | -0.11 | $11,000 | |
02/26/2021 | Q4 2020 | -$0.33 | -$0.42 | -0.09 | $11,000 | |
11/09/2020 | Q3 2020 | -$0.31 | -$0.33 | -0.02 | $439,200 | $11,000 |
08/07/2020 | Q2 2020 | -$0.30 | -$0.33 | -0.03 | $306,000 | $796,000 |
05/08/2020 | Q1 2020 | -$0.38 | -$0.35 | 0.03 | $11,000 | |
02/28/2020 | Q4 2019 | -$0.38 | -$0.34 | 0.04 | $42,000 |
Mersana Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
In the previous quarter, Mersana Therapeutics, Inc. (:MRSN) reported $-0.09 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.18 by $0.09.
The conference call for Mersana Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Mersana Therapeutics, Inc.'s latest earnings report can be read online.
Mersana Therapeutics, Inc. (:MRSN) has a recorded annual revenue of $36.86 M.
Mersana Therapeutics, Inc. (:MRSN) has a recorded net income of $36.86 M. Mersana Therapeutics, Inc. has generated $-1.48 earnings per share over the last four quarters.
Mersana Therapeutics, Inc. (:MRSN) has a price-to-earnings ratio of -2.66 and price/earnings-to-growth ratio is -0.09.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED